Press-release for stocks for lannett co inc for SNYNF

LANNETT SHARES UPDATE
Published: 2023-04-04 (Crawled : 11:00) - prnewswire.com
LCI | $0.6855 0.0% 19K

| -63.05% | O: 3.93% H: 0.0% C: -47.57%
SNY | News | $46.11 0.68% 0.7% 3.5M

| -15.25% | O: -0.1% H: 0.0% C: 0.0%
update

| 6.43% | O: -2.01% H: 0.88% C: 0.88%
LCI | $0.6855 0.0% 19K

| 42.95% | O: 2.7% H: 5.82% C: 5.33%
SNY | News | $46.11 0.68% 0.7% 3.5M

| 6.49% | O: -0.46% H: 0.0% C: 0.0%
patent device glargine program insulin

LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE
Published: 2022-08-31 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K

| 16.37% | O: 0.75% H: 1.98% C: 1.98%
LCI | $0.6855 0.0% 19K

| 33.98% | O: 0.84% H: 2.36% C: 1.8%
SNY | News | $46.11 0.68% 0.7% 3.5M

| 11.94% | O: 1.1% H: 0.0% C: 0.0%
biosimilar glargine trial insulin

LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
Published: 2022-08-24 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K

| 9.06% | O: -4.66% H: 0.0% C: -1.69%
LCI | $0.6855 0.0% 19K

| 17.09% | O: -2.05% H: 9.05% C: 7.78%
SNY | News | $46.11 0.68% 0.7% 3.5M

| 12.64% | O: -1.48% H: 0.0% C: 0.0%
results

LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
Published: 2022-06-01 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K

| -13.57% | O: -0.33% H: 2.59% C: 2.59%
LCI | $0.6855 0.0% 19K

| 20.68% | O: -0.92% H: 1.85% C: -8.33%
SNY | News | $46.11 0.68% 0.7% 3.5M

| -13.03% | O: 1.32% H: 0.0% C: 0.0%
biosimilar glargine trial insulin

Lannett Initiates Pivotal Clinical Trial For Biosimilar Insulin Glargine
Published: 2022-03-29 (Crawled : 12:00) - biospace.com/
LCI | $0.6855 0.0% 19K